Table 2 Studies with biologic agents
From: Systemic therapy for recurrent or metastatic salivary gland malignancies
| Author (year) | Regimen | No of patients | Histology | Progression required | ORR | CBR | Median OS (months) |
|---|---|---|---|---|---|---|---|
| Haddad et al. [18] | Trastuzumab | 14 | Ad (7), ACC (2), MEC (3), others (2) | No | 8 % | 8 % | NR |
| Hotte et al. [23] | Imatinib | 16 | ACC (16) | No | 0 % | 56 % | 7 |
| Pfeffer et al. [24] | Imatinib | 10 | ACC (10) | No | 0 % | 20 % | NR |
| Guigay et al. [25] | Imatinib | 17 | ACC (17) | Yes | 13 % | 47 % | NR |
| Agulnik et al. [19] | Lapatinib | 39 | Ad (7), ACC (20), MEC (2), others (11) | Yes | 0 % | 78 % | NR (ACC), 13.8 (non-ACC) |
| Locati et al. [20] | Cetuximab | 30 | ACC (23), MEC (2), others (5) | No | 0 % | 80 % | NR |
| Chau et al. [27] | Sunitinib | 14 | ACC (14) | Yes | 0 % | 85 % | 18.7 |
| Jaspers et al. [44] | Bicalutamide | 10 | SDC (10) | No | 20 % | 50 % | 12 |
| Locati et al. [29] | Sorafenib | 37 | ACC (19), others (18) | No | 16 % | 73 % | NR |
| Thomson et al. [28] | Sorafenib | 23 | ACC (23) | No | 11 % | 79 % | 19.6 |
| Kim et al. [34] | Everolimus | 34 | ACC (34) | Yes | 0 % | 79 % | 23.7 |
| Goncalves et al. [37] | Vorinostat | 30 | ACC (30) | No | 3 % | 87 % | NR |
| Hoover et al. [36] | Nelfinavir | 15 | ACC (15) | Yes | 0 % | 47 % | NR |
| Ho A. et al. [30] | Axitinib | 33 | ACC (33) | Yes | 9 % | 85 % | NR |
| Locati et al. [43] | Bicalutamide + Triptorelin | 17 | SDC (17) | No | 65 % | 88 % | 44 |
| Wong et al. [26] | Dasatinib | 54 | ACC (40), others (14) | Yes | 2 % | 50 % | 14.5 (ACC), NR (non-ACC) |
| Jakob et al. [21] | Gefitinib | 36 | Ad (9), ACC (18), MEC (2), others (6) | No | 0 % | 59 % | 25.9 (ACC); 16 (non-ACC) |
| Dillon et al. [32] | Dovitinib | 35 | ACC (35) | Yes | 6 % | 71 % | 22.1 |
| Ho A. et al. [35] | MK-2206 | 16 | ACC (16) | Yes | 0 % | 93 % | NR |
| Keam et al. [31] | Dovitinib | 32 | ACC (32) | Yes | 3 % | 94 % | NR |